Pulse Biosciences Shifts Focus to Catheter Electrophysiology Tech

Pulse Biosciences Inc. has mapped out a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System.

“The European feasibility data from over 150 patients sends a definitive message,” Pulse Biosciences Co-Chairman Bob Duggan said. “The nPulse clinical performance demonstrates a clear potential to change clinical practice for the health treatment of millions of patients. Our mission to support this program deserves our highest priority, and we are updating our capital allocation to align with this opportunity.”

This initiative follows the announcement of clinical outcomes from the company’s 150-patient European feasibility study, which demonstrated that nsPFA delivers a unique combination of speed, safety, and long-term durable efficacy in treating atrial fibrillation (AFib).

The Data: Unprecedented Clinical Outcomes

The decision to centralize resources on the Cardiac Catheter program is backed by data that positions nPulse as a best-in-class solution:

• Complete (100%) procedural success at six months: Seventy-five of 75 patients evaluated achieved acute Pulmonary Vein Isolation (PVI) success.
• 96% sustained success at 12 months: Long-term follow-up (45 of 47 patients) confirmed highly durable PVI, exceeding traditional expectations in a field where approximately 20% to 25% recurrence is common.
• Industry-leading procedural efficiency:
  • Left atrial dwell time: 21.0 ± 13.3 minutes; this would reduce the time spent inside the heart.
  • Total procedure time: Averaged 65 minutes, including only 9.8 minutes of fluoroscopy.
  • Ease of use: Success was achieved with an average of 16.1 applications per procedure.
• Safety profile: A low 1.3% rate of serious adverse events (SAEs) related to the primary safety endpoint.

“We are thrilled to be allocating additional resources to the vast potential of our catheter-based EP program. We are fortifying a program that has already shown the potential to be first-in-class and best-in-class,” Pulse Biosciences Co-Chairman/CEO Paul LaViolette stated.

Strategic Resource Alignment: Focus on High-Value Growth

To capitalize on these results, Pulse Biosciences is modifying its capital allocation to prioritize the electrophysiology (EP) market development program:

• Primary focus: The majority of R&D and clinical investment is now dedicated to the nPulse Cardiac Catheter program’s upcoming pivotal IDE study in the United States and Europe, and corresponding regulatory submission.
• Surgical program calibration: While the company remains committed to the Surgical Clamp IDE enrollment, it will reduce short-term market development investments in cardiac surgery.
• Soft-tissue ablation optimization: Operations for the percutaneous soft-tissue ablation system have been streamlined to reduce spend on sales and marketing and focusing on market development by progressing the Vybrance Percutaneous Electrode System towards an on-label indication for treating benign thyroid nodules, driving real-world utilization data, and validating reimbursement rates, thereby allowing for a reduction in investment that can be redirected to the catheter program.

Late breaking clinical data on the treatment of AFib using the nPulse Cardiac Catheter System has been accepted for presentation at Heart Rhythm 2026 in Chicago. A late-breaking data presentation by Vivek Reddy, M.D., director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital in New York, N.Y., will include additional 12-month follow-up data from the nPulse Cardiac Catheter first-in-human feasibility study. The presentation is scheduled for April 25.

Pulse Biosciences is a bioelectric medicine company committed to health innovation that can potentially improve patients’ quality of life. The company’s proprietary nPulse technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. Pulse Biosciences is actively pursuing the development of its nPulse technology to treat atrial fibrillation and in a select few other markets, such as surgical soft tissue ablation.